Combined Vascular Endothelial Growth Factor–Targeted Therapy and Radiotherapy for Rectal Cancer: Theory and Clinical Practice
- 1 October 2006
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 33, S35-S40
- https://doi.org/10.1053/j.seminoncol.2006.08.007
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Radiation Combined With Antiangiogenic and Antivascular AgentsSeminars in Radiation Oncology, 2006
- Lessons from phase III clinical trials on anti-VEGF therapy for cancerNature Clinical Practice Oncology, 2006
- Angiogenesis in life, disease and medicineNature, 2005
- Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer PatientsJournal of Clinical Oncology, 2005
- Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiationCancer Cell, 2004
- Preoperative versus Postoperative Chemoradiotherapy for Rectal CancerNew England Journal of Medicine, 2004
- Tumor Response to Radiotherapy Regulated by Endothelial Cell ApoptosisScience, 2003
- Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal CancerNew England Journal of Medicine, 2001
- An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinomaInternational Journal of Radiation Oncology*Biology*Physics, 1997